CSF samples from a first validation cohort (VC) of RR-MS patients (MS VC1) were tested for several pro-inflammatory and anti-inflammatory cytokines (IFN-γ, TNF, IL-10, and IL-6), chemokines (CXC motif chemokine ligand 12 (CXCL12), CXCL13, CXCL10, C-C motif ligand 19 (CCL19), neurofilament light chain (NF-L) and sCD27. This evidence concerns the gene CXCL13 and myeloid sarcoma.